NRA-Quetiapine XR: Some lots exceed the intake limit of N-nitroso-desalkyl-quetiapine (NDAQ)
Brand(s)
Last updated
Summary
Product
NRA-Quetiapine XR
Issue
Health products - Product quality
What to do
Consult your healthcare provider prior to discontinuing use of the affected product, or for any health concerns.
Distribution
National
Affected products
Brand |
Product Name |
Market Authorization |
Dosage Form |
Strength |
Lot numbers |
|---|---|---|---|---|---|
NORA PHARMA INC |
NRA-Quetiapine XR |
DIN 02510677 |
Tablet (Extended-Release) |
QUETIAPINE FUMARATE 50mg |
M2216571 & M2214003 |
Issue
Affected lots may exceed the established acceptable intake limit for N-nitroso-desalkyl-quetiapine (NDAQ)
What you should do
- Verify if your product is affected.
- Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns.
- Contact the recalling firm if you have any questions about the recall.
- Report any health product related side effects to Health Canada.
- Report any other health product safety complaints to Health Canada.
Additional information
Background
Depth of recall: Retailers
Details
Original published date:
Alert / recall type
Health product recall
Category
Health products - Drugs
Companies
Nora Pharma Inc.
1565 boulevard Lionel-Boulet
Varennes, QC
J3X 1P7
Published by
Health Canada
Audience
General public
Healthcare
Industry
Distribution
National
Recall class
Type II
Identification number
RA-77266
Get notified
Receive notifications for new and updated recalls and alerts by category.